Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1060

1.

Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.

Hiraoka A, Kumada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Yokohama K, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M.

Liver Cancer. 2020 Jan;9(1):73-83. doi: 10.1159/000503031. Epub 2019 Oct 18.

2.

Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies.

Kariyama K, Nouso K, Wakuta A, Oonishi A, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kumada T.

Liver Cancer. 2020 Jan;9(1):41-49. doi: 10.1159/000502479. Epub 2019 Oct 22.

3.

Neutrophil-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.

Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y.

Liver Int. 2020 Feb 17. doi: 10.1111/liv.14405. [Epub ahead of print]

PMID:
32064740
4.

The natural course of the paravertebral muscles after the onset of osteoporotic vertebral fracture.

Takahashi S, Hoshino M, Takayama K, Sasaoka R, Tsujio T, Yasuda H, Kanematsu F, Kono H, Toyoda H, Ohyama S, Hori Y, Nakamura H.

Osteoporos Int. 2020 Feb 14. doi: 10.1007/s00198-020-05338-8. [Epub ahead of print]

PMID:
32060561
5.

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.

Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN; Collaborators.

Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043. [Epub ahead of print]

6.

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.

Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S.

Cancers (Basel). 2020 Jan 26;12(2). pii: E293. doi: 10.3390/cancers12020293.

7.

Molecular and Regulatory Mechanisms of Desensitization and Resensitization of GABAA Receptors with a Special Reference to Propofol/Barbiturate.

Kang Y, Saito M, Toyoda H.

Int J Mol Sci. 2020 Jan 15;21(2). pii: E563. doi: 10.3390/ijms21020563. Review.

8.

Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.

Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T.

J Gastroenterol Hepatol. 2020 Jan 16. doi: 10.1111/jgh.14982. [Epub ahead of print]

PMID:
31950525
9.

Kinetic analysis of sequential metabolism of triazolam and its extrapolation to humans using an entero-hepatic two-organ microphysiological system.

Arakawa H, Sugiura S, Kawanishi T, Shin K, Toyoda H, Satoh T, Sakai Y, Kanamori T, Kato Y.

Lab Chip. 2020 Feb 7;20(3):537-547. doi: 10.1039/c9lc00884e. Epub 2020 Jan 13.

PMID:
31930237
10.

Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.

Atsukawa M, Tsubota A, Takaguchi K, Toyoda H, Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K.

J Gastroenterol Hepatol. 2019 Dec 27. doi: 10.1111/jgh.14965. [Epub ahead of print]

PMID:
31881554
11.

Editorial: the emergence of non-hypervascular hypointense nodules in Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. Authors' reply.

Toyoda H, Yasuda S, Kumada T.

Aliment Pharmacol Ther. 2020 Jan;51(1):169-170. doi: 10.1111/apt.15546. No abstract available.

PMID:
31850587
12.

Laborless, Automated Microfluidic Tandem Cell Processor for Visualizing Intracellular Molecules of Mammalian Cells.

Mu T, Toyoda H, Kimura Y, Yamada M, Utoh R, Umeno D, Seki M.

Anal Chem. 2020 Feb 4;92(3):2580-2588. doi: 10.1021/acs.analchem.9b04288. Epub 2019 Dec 26.

PMID:
31822057
13.

Characteristic radiological findings for revision surgery after balloon kyphoplasty.

Takahashi S, Hoshino M, Yasuda H, Hori Y, Ohyama S, Terai H, Hayashi K, Tsujio T, Kono H, Suzuki A, Tamai K, Toyoda H, Dohzono S, Sasaoka R, Kanematsu F, Terakawa M, Nakamura H.

Sci Rep. 2019 Dec 6;9(1):18513. doi: 10.1038/s41598-019-55054-5.

14.

The chances of hepatic resection curing hepatocellular carcinoma.

Cucchetti A, Zhong J, Berhane S, Toyoda H, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Ercolani G, Mazzaferro V, Kudo M, Cescon M, Pinna AD, Kumada T, Johnson PJ.

J Hepatol. 2019 Nov 30. pii: S0168-8278(19)30703-2. doi: 10.1016/j.jhep.2019.11.016. [Epub ahead of print]

PMID:
31790765
15.

HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.

Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH; REAL-C Investigators, Ahn SB, Azuma K, Dohmen K, Yoon Jeong J, Jung JH, Kajiwara E, Kato M, Kawano A, Koyanagi T, Ooho A, Park SH, Satoh T, Shimoda S, Song DS, Takahashi K, Yeh ML, Yoon EL.

Clin Infect Dis. 2019 Nov 28. pii: ciz1160. doi: 10.1093/cid/ciz1160. [Epub ahead of print]

PMID:
31777940
16.

Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.

Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T.

Cancer Sci. 2020 Feb;111(2):334-342. doi: 10.1111/cas.14251. Epub 2019 Dec 28.

17.

Improvement in Patient Mental Well-being After Surgery for Cervical Spondylotic Myelopathy.

Tamai K, Suzuki A, Terai H, Hoshino M, Toyoda H, Takahashi S, Ohyama S, Hori Y, Yabu A, Nakamura H.

Spine (Phila Pa 1976). 2019 Nov 19. doi: 10.1097/BRS.0000000000003337. [Epub ahead of print]

PMID:
31770327
18.

Impact of Sarcopenia on Clinical Outcomes of Minimally Invasive Lumbar Decompression Surgery.

Toyoda H, Hoshino M, Ohyama S, Terai H, Suzuki A, Yamada K, Takahashi S, Hayashi K, Tamai K, Hori Y, Nakamura H.

Sci Rep. 2019 Nov 12;9(1):16619. doi: 10.1038/s41598-019-53053-0.

19.

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.

Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A.

Clin Gastroenterol Hepatol. 2020 Mar;18(3):728-735.e4. doi: 10.1016/j.cgh.2019.11.012. Epub 2019 Nov 8.

20.

A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma.

Amoros R, King R, Toyoda H, Kumada T, Johnson PJ, Bird TG.

Metron. 2019;77(2):67-86. doi: 10.1007/s40300-019-00151-8. Epub 2019 May 30.

21.

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.

Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ.

Hepatology. 2019 Nov 7. doi: 10.1002/hep.31022. [Epub ahead of print]

PMID:
31698504
22.

Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease.

Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Toyoda H, Kumada T, Fujishiro M.

Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001587. [Epub ahead of print]

PMID:
31688305
23.

[Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].

Okabe T, Katoh M, Kano M, Okazaki R, Tanaka Y, Toyoda H, Ueno M.

Yakugaku Zasshi. 2019;139(11):1435-1448. doi: 10.1248/yakushi.19-00082. Japanese.

24.

Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response.

Itami-Matsumoto S, Hayakawa M, Uchida-Kobayashi S, Enomoto M, Tamori A, Mizuno K, Toyoda H, Tamura T, Akutsu T, Ochiya T, Kawada N, Murakami Y.

Biomedicines. 2019 Nov 3;7(4). pii: E87. doi: 10.3390/biomedicines7040087.

25.

Heparan Sulfate Structure Affects Autophagy, Lifespan, Responses to Oxidative Stress, and Cell Degeneration in Drosophila parkin Mutants.

Reynolds-Peterson C, Xu J, Zhao N, Cruse C, Yonel B, Trasorras C, Toyoda H, Kinoshita-Toyoda A, Dobson J, Schultheis N, Jiang M, Selleck S.

G3 (Bethesda). 2020 Jan 7;10(1):129-141. doi: 10.1534/g3.119.400730.

26.

Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis.

Tada T, Kumada T, Toyoda H, Yasuda S, Sone Y, Hashinokuchi S, Ogawa S, Oguri T, Kamiyama N, Chuma M, Akita T, Tanaka J.

Hepatol Res. 2020 Feb;50(2):190-198. doi: 10.1111/hepr.13442. Epub 2019 Dec 29.

PMID:
31661724
27.

Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching.

Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y.

Hepatol Res. 2020 Jan;50(1):75-83. doi: 10.1111/hepr.13427. Epub 2019 Dec 6.

PMID:
31660700
28.

Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.

Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH.

Am J Gastroenterol. 2020 Feb;115(2):271-280. doi: 10.14309/ajg.0000000000000428.

PMID:
31634265
29.

Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West.

Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH.

Hepatology. 2019 Oct 14. doi: 10.1002/hep.30988. [Epub ahead of print]

PMID:
31610027
30.

Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.

Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T.

J Gastroenterol Hepatol. 2019 Oct 14. doi: 10.1111/jgh.14874. [Epub ahead of print]

PMID:
31609495
31.

The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C.

Toyoda H, Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J, Kumada T.

Aliment Pharmacol Ther. 2019 Dec;50(11-12):1232-1238. doi: 10.1111/apt.15490. Epub 2019 Oct 6.

PMID:
31588590
32.

Epigenome-wide association study of narcolepsy-affected lateral hypothalamic brains, and overlapping DNA methylation profiles between narcolepsy and multiple sclerosis.

Shimada M, Miyagawa T, Takeshima A, Kakita A, Toyoda H, Niizato K, Oshima K, Tokunaga K, Honda M.

Sleep. 2020 Jan 13;43(1). pii: zsz198. doi: 10.1093/sleep/zsz198.

PMID:
31556946
33.

Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy.

Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH.

J Infect Dis. 2020 Jan 14;221(3):389-399. doi: 10.1093/infdis/jiz477.

PMID:
31550363
34.

Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K; On behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019;97(6):334-340. doi: 10.1159/000502095. Epub 2019 Aug 29.

PMID:
31466068
35.

Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium.

Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH; REAL-C Investigators.

Hepatol Int. 2019 Sep;13(5):587-598. doi: 10.1007/s12072-019-09974-z. Epub 2019 Aug 28.

PMID:
31463665
36.

Impact of Hemodialysis on Surgical Outcomes and Mortality Rate after Lumbar Spine Surgery: A Matched Cohort Study.

Hori Y, Takahashi S, Terai H, Hoshino M, Toyoda H, Suzuki A, Hayashi K, Tamai K, Ohyama S, Nakamura H.

Spine Surg Relat Res. 2018 Aug 25;3(2):151-156. doi: 10.22603/ssrr.2018-0025. eCollection 2019 Apr 27.

37.

Surgical Treatment of a Patient with Prolonged Exacerbation of Hirayama Disease.

Dohzono S, Toyoda H, Tamura A, Hayashi K, Terai H, Nakamura H.

Spine Surg Relat Res. 2018 Aug 25;3(1):95-97. doi: 10.22603/ssrr.2018-0037. eCollection 2019 Jan 25. No abstract available.

38.

Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease.

Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Toyoda H, Kumada T, Fujishiro M.

Nutr Cancer. 2019 Aug 21:1-8. doi: 10.1080/01635581.2019.1653474. [Epub ahead of print]

PMID:
31433263
39.

Sarcopenia is related to spinal sagittal imbalance in patients with spinopelvic mismatch.

Ohyama S, Hoshino M, Terai H, Toyoda H, Suzuki A, Takahashi S, Hayashi K, Tamai K, Hori Y, Nakamura H.

Eur Spine J. 2019 Sep;28(9):1929-1936. doi: 10.1007/s00586-019-06066-2. Epub 2019 Jul 17.

PMID:
31317307
40.

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019;97(5):277-285. doi: 10.1159/000501281. Epub 2019 Jul 15.

PMID:
31307035
41.

Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.

Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T.

J Viral Hepat. 2019 Nov;26(11):1266-1275. doi: 10.1111/jvh.13170. Epub 2019 Aug 9.

PMID:
31278795
42.

The mechanosensitive channel YbdG from Escherichia coli has a role in adaptation to osmotic up-shock.

Amemiya S, Toyoda H, Kimura M, Saito H, Kobayashi H, Ihara K, Kamagata K, Kawabata R, Kato S, Nakashimada Y, Furuta T, Hamamoto S, Uozumi N.

J Biol Chem. 2019 Aug 16;294(33):12281-12292. doi: 10.1074/jbc.RA118.007340. Epub 2019 Jun 29.

PMID:
31256002
43.

Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model.

Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J.

J Med Virol. 2019 Oct;91(10):1837-1844. doi: 10.1002/jmv.25533. Epub 2019 Jul 16.

44.

Increased advanced glycation end products in hypertrophied ligamentum flavum of diabetes mellitus patients.

Maruf MH, Suzuki A, Hayashi K, Habibi H, Salimi H, Terai H, Tamai K, Hoshino M, Toyoda H, Yamada K, Takahashi S, Ohyama S, Hori Y, Nakamura H.

Spine J. 2019 Oct;19(10):1739-1745. doi: 10.1016/j.spinee.2019.06.001. Epub 2019 Jun 10.

PMID:
31195134
45.

Clinical Impact of Cervical Imbalance on Surgical Outcomes of Laminoplasty: A Propensity Score-Matching Analysis.

Tamai K, Suzuki A, Yabu A, Terai H, Hoshino M, Toyoda H, Takahashi S, Ohyama S, Hori Y, Nakamura H.

Clin Spine Surg. 2020 Feb;33(1):E1-E7. doi: 10.1097/BSD.0000000000000849.

PMID:
31162189
46.

The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.

Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J.

J Gastroenterol. 2019 Sep;54(9):829-836. doi: 10.1007/s00535-019-01595-5. Epub 2019 Jun 3.

PMID:
31161311
47.

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jul;8(8):3719-3728. doi: 10.1002/cam4.2241. Epub 2019 May 24.

48.

Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.

Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T.

Open Forum Infect Dis. 2019 Apr 15;6(5):ofz185. doi: 10.1093/ofid/ofz185. eCollection 2019 May.

49.

Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease.

Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, Tanaka J.

J Gastroenterol Hepatol. 2019 Nov;34(11):2011-2018. doi: 10.1111/jgh.14734. Epub 2019 Jun 7.

PMID:
31115065
50.

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.

Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH.

J Hepatol. 2019 Sep;71(3):473-485. doi: 10.1016/j.jhep.2019.04.017. Epub 2019 May 13.

PMID:
31096005

Supplemental Content

Loading ...
Support Center